6-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

Form6-K

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16

UNDERTHE SECURITIES EXCHANGE ACT OF 1934

Forthe month of March 2025

CommissionFile Number: 001-42527

BaselMedical Group Ltd

6Napier Road,

Unit#02-10/11 Gleneagles Medical Centre

Singapore258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

PubliclyTradable Shares

On February 26, 2025, Basel Medical Group Ltd (the “Company”) closed its initial public offering (the “IPO”) of 2,205,000 ordinary shares, no par value (the “Ordinary Shares”). The Company completed the IPO pursuant to its registration statement on Form F-1 (File No. 333-282096) (the “Registration Statement”), which was initially filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 13, 2024, as amended, and declared effective by the SEC on February 18, 2025. The Registration Statement also registered 2,000,000 Ordinary Shares for resale by certain selling shareholders in a resale prospectus. As of March 6, 2025, the number of publicly tradable shares of the Company is 4,205,000 Ordinary Shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.